Fundraising Fox

Enveric Biosciences

NASDAQ: ENVB

Cambridge, US · Delaware corporation

Enveric Biosciences is a biotechnology company developing neuroplastogenic small-molecule drugs for neuropsychiatric and mental health disorders. It uses a proprietary discovery platform called The Psybrary to build an intellectual property portfolio of novel molecules targeting specific mental health indications.

BiotechHealthtechMental Health

Founders & leadership

KM
Kevin M. CoveneyChief Financial Officer
JE
Joseph E. TuckerChief Executive Officer and Director
SD
Srinidhi DevanurExecutive Vice Chairman
VP
Viraj PatelChief Financial Officer
BK
Brent KeltonChief Executive Officer
DA
Dimitrios AngelisNamed on SEC filing
JS
James ShadNamed on SEC filing
DL
David LuciNamed on SEC filing
RS
Robert ShawahNamed on SEC filing

Board

MS
Marcus SchabackerBoard director
SD
Sheila DeWittBoard director
FP
Frank PasqualoneBoard director

Reported raises · per SEC filings

Form D private placements

$25.9M disclosed across 5 of 8 rounds · 2018–2026

▶$5MraisedMay 2026 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kevin M. CoveneyExecutive Officer
  • Michael SchabackerDirector
  • George W. KeglerDirector
  • Sheila DeWittDirector
  • Joseph E. TuckerExecutive Officer, Director
  • Frank PasqualoneDirector
  • Michael D. WebbDirector
Offering amount
$5M
Amount sold
$5M
Sales commissions
$350K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Apr 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedFeb 2026 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael D. WebbDirector
  • Sheila DeWittDirector
  • Joseph E. TuckerExecutive Officer, Director
  • Kevin M. CoveneyExecutive Officer
  • Frank PasqualoneDirector
  • Marcus SchabackerDirector
  • George W. KeglerDirector
Offering amount
$1.5M
Amount sold
$1.5M
Sales commissions
$101.5K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jan 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$106.6KraisedDec 2025 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sheila DeWittDirector
  • George W. KeglerDirector
  • Kevin M. CoveneyExecutive Officer
  • Marcus SchabackerDirector
  • Frank PasqualoneDirector
  • Michael D. WebbDirector
  • Joseph E. TuckerExecutive Officer, Director
Offering amount
$106.6K
Amount sold
$106.6K
Sales commissions
$217.9K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Dec 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedOct 2025 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Marcus SchabackerDirector
  • Kevin M. CoveneyExecutive Officer
  • Sheila DeWittDirector
  • Joseph E. TuckerExecutive Officer, Director
  • Frank PasqualoneDirector
  • Michael D. WebbDirector
  • George W. KeglerDirector
Sales commissions
$155.3K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Sep 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.8MraisedApr 2023 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph TuckerExecutive Officer, Director
  • Bob DagherExecutive Officer
  • Marcus SchabackerDirector
  • Douglas LindDirector
  • Frank PasqualoneDirector
  • Peter FacchiniExecutive Officer
  • George KeglerDirector
  • Michael D. WebbDirector
  • Bevin O'NeilDirector
  • Kevin CoveneyExecutive Officer
  • Avani KanubaddiExecutive Officer
Offering amount
$12.8M
Amount sold
$12.8M
Sales commissions
$560K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jul 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.4MofferedFeb 2021 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David JohnsonExecutive Officer, Director
  • Avani KanubaddiExecutive Officer, Director
  • Sol MayerDirector
  • Marcus SchabackerDirector
  • John Van BuitenExecutive Officer
  • George KeglerDirector
Offering amount
$8.4M
First sale
Feb 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.2MofferedJan 2021 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Marcus SchabackerDirector
  • Sol MayerDirector
  • George KeglerDirector
  • Avani KanubaddiExecutive Officer
  • John Van BuitenExecutive Officer
  • David JohnsonExecutive Officer, Director
Offering amount
$8.2M
First sale
Jan 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.6MraisedAug 2018 · 4 investors · Business Services
Rule 506(b)
Officers, directors & promoters on the filing
  • Dimitrios AngelisDirector
  • Srinidhi DevanurExecutive Officer, Director
  • James ShadDirector
  • Viraj PatelExecutive Officer
  • David LuciDirector
  • Robert ShawahDirector
  • Brent KeltonExecutive Officer
Offering amount
$6.6M
Amount sold
$6.6M
Sales commissions
$456.9K
Placement agents
A.G.P. / Alliance Global Partners
First sale
Jul 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 6

by search overlap
Seeking Alpha14 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood13 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Perplexity13 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Tradingview13 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanks12 shared keywordsFinancial analysis and stock research platform.
Interactive Strength Acquires Ergatta11 shared keywordsFidelity provides brokerage and investing services for individual retail investors, including commission-free online trading of US stocks and ETFs and fractional share purchases starting at $1. It positions itself as a personal finance and investment provider serving customers pursuing long-term financial goals.

Companies competing with Enveric Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Enveric Biosciences do?
Enveric Biosciences is a biotechnology company developing neuroplastogenic small-molecule drugs for neuropsychiatric and mental health disorders. It uses a proprietary discovery platform called The Psybrary to build an intellectual property portfolio of novel molecules targeting specific mental health indications.
How much funding has Enveric Biosciences raised?
Enveric Biosciences has disclosed $25.9M raised across 5 of its 8 known rounds.
Where is Enveric Biosciences headquartered?
Enveric Biosciences is headquartered in Cambridge, US.